Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France
M. Kandel(Institut Gustave Roussy), Isabelle Borget(Université Paris-Sud), A. Bardet(Université Paris-Sud), M. Beylot‐Barry, M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), Célèste Lebbé(Inserm), S. Dalac(CHU Dijon Bourgogne), Jean‐Philippe Arnault(Centre Hospitalier Universitaire Amiens-Picardie), Thierry Lesimple, Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), F. Granel‐Brocard(Centre Hospitalier Régional et Universitaire de Nancy), A. Dupuy(Hôpital Pontchaillou), Henri Montaudié(Hôpital l'Archet), F. Brunet‐Possenti(Université Claude Bernard Lyon 1), E. Maubec(Délégation Paris 7), F. Aubin, Délphine Legoupil(Centre Hospitalier Régional Universitaire de Brest), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Jean‐Jacques Grob, Stefan Michiels(Institut Gustave Roussy), B. Guillot(Université de Montpellier), Clara Allayous(Inserm), Stéphane Dalle(Mount Sinai Hospital), Laurent Mortier, Julie De Quatrebarbes(Centre Hospitalier Annecy Genevois), Pierre‐Emmanuel Stoebner(Centre Hospitalier Universitaire de Nîmes), Brigitte Dréno(Inserm)
Cited by 5
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k